Valeo Pharma sees record quarterly revenue with a triple-digit increase over 1Q 2022 | News Direct

Valeo Pharma sees record quarterly revenue with a triple-digit increase over 1Q 2022

News release by Valeo Pharma Inc.

facebook icon linkedin icon twitter icon pinterest icon email icon Vancouver | March 17, 2023 11:40 AM Eastern Daylight Time

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company had a record quarter in the three months to January 31, 2023, with revenue of $13.2 million, up 210% over 1Q 2022.

Saviuk tells Proactive this marks the 5th consecutive quarter of growth for the company, with adjusted gross profit increasing by 178% to $4.2 million from a year earlier.

Physicians prescribing Enerzair and Atectura reached 1,583 at the end of the first quarter, 39% growth for the quarter and a 799% increase year-over-year. Total annual Enerzair and Atectura prescriptions surpassed 34,000 at the end of 1Q 2023, up 1,917% year-over-year.

 

 

Contact Details

 

Proactive Canada

 

+1 604-688-8158

 

na-editorial@proactiveinvestors.com

Tags

proactiveinvestorsvaleopharmainctsxvphotcqbvphifpharmainvestinvestinginvestmentinvestorstockmarketstocksstockstockmarketnews